Navigation Links
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Date:11/29/2007

cs and clinical benefit has not been established.

Safety Assessment

The majority of adverse events reported in this study were mild to moderate in severity. The most frequently reported adverse events for VYVANSE were insomnia (8 percent), decreased appetite (6 percent), anorexia (4 percent) and upper respiratory tract infection (2 percent); for Adderall XR they were decreased appetite (4 percent), upper abdominal pain (4 percent), insomnia (2 percent), upper respiratory tract infection (2 percent) and vomiting (2 percent).

VYVANSE is currently approved in the United States for the treatment of ADHD in children aged 6 to 12 years.

Additional information about VYVANSE and Full Prescribing Information are available at http://www.vyvanse.com.

About ADHD

Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). ADHD is one of the most common psychiatric disorders in children and adolescents. The disorder is also estimated to affect 8.1 percent of adults, or approximately 9.2 million adults across the U.S. based on a retrospective survey of adults aged 18 to 44, projected to the full U.S. adult population. ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS ... release its financial results for the fiscal 2014 fourth ... trading ends on Tuesday, September 9, 2014. ... p.m. U.S. EDT on Tuesday, September 9, 2014 (Wednesday, ... Company,s financial results, commercial partnerships, and future outlook.  The ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014  Abaxis, Inc. ... manufacturing point-of-care blood instrumentation and consumables to the medical, ... Severson , Chairman and Chief Executive Officer, will present ... Ideas Conference 2014 on Tuesday, September 9, 2014 at ... the Omni Berkshire Place Hotel in New ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Colo., Oct. 7 Waleed Danho, Ph.D., Distinguished Research ... 2009 recipient of the Meienhofer Award for excellence in ... RCCPS ( http://www.rochecolorado.com/PeptideSymp09/ ). Hosted ... Boulder, RCCPS is the only global conference exclusively dedicated ...
... Biomedical Corporation, a leading developer of whole blood analyzers, ... Sanvita CBGM, LLC, has completed the acquisition of certain ... Inc. , Nova Biomedical is the sole ... Monitoring (CBGM) subsidiary has become the exclusive distributor, of ...
Cached Medicine Technology:Roche Scientist Recognized for Excellence in Peptide Chemistry 2Roche Scientist Recognized for Excellence in Peptide Chemistry 3Roche Scientist Recognized for Excellence in Peptide Chemistry 4Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medical's Subsidiary, Sanvita, Inc. 2
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... 2014 The federal judge overseeing ... http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. has ... selected for one of the proceeding’s bellwether trials. ... 2014, U.S. District Judge Joseph R. Goodwin of ... Boston Scientific’s contention that a consolidated trial would ...
(Date:8/30/2014)... Transvenous lead extraction (TLE) is clinically successful in more ... European Lead Extraction ConTRolled (ELECTRa) registry presented for the ... Maria Grazia Bongiorni, chair of the registry,s executive committee. ... electronic devices (CIED) implant procedures has grown in recent ... has increased and leads are often the cause. TLE ...
(Date:8/30/2014)... OK (PRWEB) August 30, 2014 In ... valuable, and increasingly difficult to get. Snoring and sleep ... sleep and breathing stops) robs people and their bed ... daily challenges. Up to 45% of the population snores ... have sleep apnea. Of these, only 10% have been ...
(Date:8/30/2014)... Top10BestSEOHosting.com is a well-known review website. Recently, the ... http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts is the best Windows Hosting supplier ... that Bluehost and Arvixe are excellent companies for ... Top 10 Web Hosting in 2014, is a ... offers rich features and great Windows hosting solutions ...
Breaking Medicine News(10 mins):Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2
... available in German . The stomach bacterium ... the development of gastric cancer, the third most common cause of ... Zurich have now identified a mechanism of Helicobacter pylori that damages ... up for malignant transformation. Gastric cancer is one of the ...
... Do sexualized lyrics in popular music have an impact on ... Joshua H. West, and Shane Hill from Brigham Young University ... increasing use of sexually explicit lyrics in music. Their ... , provide food for thought for educators whose focus is ...
... Academy of Sciences and the Global Medical Excellence Cluster ... College London, will host a two-day scientific conference, ... and Toxicity," that will provide a forum to ... drug discovery. Areas of focus include: how do animal ...
... published study by researchers at Columbia University,s Mailman School ... effects on children of a group of ubiquitous chemicals ... that are known to disrupt the endocrine system, and ... toys, to household building materials, to shampoos. Recent ...
... News) -- Mild cognitive impairment -- marked by a ... a stronger predictor of Alzheimer,s disease than so-called "biomarkers," ... or levels of certain proteins in cerebrospinal fluid, a ... people with mild cognitive impairment (MCI) who developed Alzheimer,s ...
... French . , A major landmark study released ... light on the state of Europe,s mental and neurological health. ... largest health challenge in the 21st century. The study also ... together with the large and increasing number of ,disorders of ...
Cached Medicine News:Health News:Stomach bacterium damages human DNA 2Health News:Songs about sex - how they affect kids 2Health News:New York Academy of Sciences and GMEC host forum on value of animal models in drug discovery 2Health News:New York Academy of Sciences and GMEC host forum on value of animal models in drug discovery 3Health News:Prenatal exposure to phthalates linked to decreased mental and motor development 2Health News:Short-Term Memory Loss May Be Best Predictor of Alzheimer's 2Health News:The size and burden of mental disorders in Europe 2Health News:The size and burden of mental disorders in Europe 3
Titanium. Curved shafts with 5.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.3 inches....
Angled 45 degree shafts 8 mm from tip to bend with 5 mm tying platform. Serrated handle with dull finish. Overall length 3.3 inches....
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches....
Straight shafts with 4 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches....
Medicine Products: